Top 10 Best-Performing Biopharma Stocks of 2026 YTD (Corrected)
A source-backed ranking of the 10 biopharma stocks with the highest YTD returns through June 27, 2026, drawn from the full NASDAQ+NYSE biotech universe (1,072 names). Q32 Bio (+283%), Tango Therapeutics (+252%), Veradermics (+236%), Oruka (+221%), Enliven (+222%), Twist Bioscience (+208%), Absci (+202%), Liquidia (+149%), Dianthus (+140%), Revolution Medicines (+130%). Includes a methodology correction from an earlier version of this analysis.
Editor’s note: an earlier version of this post used a hand-curated candidate list of ~80 biotech names and missed Revolution Medicines and 7-8 other top performers. This corrected version uses the full NASDAQ + NYSE biotech / pharma / drug universe (1,072 names with $200M+ market cap), filters out mid-recovery stocks (more than 25% below 52-week high), and ranks by hard YTD data via Yahoo Finance. The corrected top 10 has 8 different names from the earlier version — only Absci survives in both rankings.
The 2026 biopharma rally has been a small/mid-cap clinical-stage story — not the mega-cap incumbents. Below is the corrected ranking of the top 10 best-performing biopharma stocks through June 27, 2026, drawn from the full NASDAQ + NYSE biotech universe and filtered for genuine momentum (near 52-week highs).
The list is dominated by 2023-2024 IPO clinical-stage biotechs that re-rated aggressively on 2026 Phase 2 readouts in autoimmune, precision oncology, dermatology, and pulmonary indications. The only company from the original (v1) ranking that survives in the corrected top 10 is Absci (+202%) — the AI-bio clinical proof point that anchors the 2026 narrative.
1. Q32 Bio (NASDAQ: QTTB) — +283% YTD | near 52-week high
Autoimmune biotech developing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody for alopecia areata. Stock ripped in 2026 on the SIGNAL-AA Phase 2 readout and the company’s strategic refocus on autoimmune disease after selling the Akebia / ADX-097 complement asset. Top-line Part B alopecia areata data expected mid-2026.
What propelled it: Clean Phase 2 catalyst path + autoimmune refocused pipeline + de-risked balance sheet post-Akebia sale.
2. Tango Therapeutics (NASDAQ: TNGX) — +252% YTD | near 52-week high
Precision oncology biotech developing synthetic-lethality drugs, with lead asset vopimetostat (PRMT5 inhibitor) for pancreatic and lung cancer. The April 2026 readout — 92% ORR in a pancreatic cancer combination cohort — was a category-defining moment for the PRMT5 mechanism. The company is now advancing to a pivotal trial in 2L MTAP-deleted pancreatic cancer.
What propelled it: 92% ORR pancreatic cancer data + synthetic-lethality mechanism validated + clear path to pivotal trial.
3. Veradermics (NYSE: MANE) — +236% YTD | near 52-week high
Dermatology biotech developing a new topical minocycline formulation for acne vulgaris. Recent IPO; stock has been climbing steadily post-listing on Phase 2 efficacy data and Strong Buy analyst consensus (price targets $120+, May 2027).
What propelled it: Recent IPO + clinical-stage acne program + clean analyst conviction.
4. Oruka Therapeutics (NASDAQ: ORKA) — +221% YTD | near 52-week high
Clinical-stage biotech developing ORKA-001, a long-acting IL-23 inhibitor for moderate-to-severe plaque psoriasis. Phase 2 data showed high efficacy and flexible dosing options. The stock has been re-rating aggressively on the psoriasis read-through — the IL-23 / IL-17A/F space is one of the highest-conviction dermatology targets.
What propelled it: Best-in-class IL-23 Phase 2 data + huge psoriasis market + multiple ongoing Phase 2/3 readouts.
5. Enliven Therapeutics (NYSE: ELVN) — +222% YTD | near 52-week high
Clinical-stage precision oncology biotech developing allosteric kinase inhibitors. Stock has been rising on pipeline progress (CML, GIST, etc.) and investor enthusiasm for the allosteric approach in oncology.
What propelled it: Allosteric-kinase platform + multiple clinical-stage assets + oncology re-rating.
6. Twist Bioscience (NASDAQ: TWST) — +208% YTD | near 52-week high
Synthetic DNA + AI-driven antibody discovery platform. Revenue growth in the synthetic biology and antibody-design business has been accelerating through 2026. The combo of (a) high-margin revenue scale-up and (b) the AI-antibody narrative re-rate has pushed the stock to near all-time highs.
What propelled it: Synthetic biology revenue acceleration + AI-bio rerate.
7. Absci Corporation (NASDAQ: ABSI) — +202% YTD | near 52-week high
The only company from the v1 ranking that survives the comprehensive re-rank. Generative AI antibody design platform; ABS-201 (anti-prolactin receptor for androgenetic alopecia) entered Phase 1/2a HEADLINE trial in early 2026 — the first clinical proof point of Absci’s generative AI drug creation platform. Interim efficacy data expected H2 2026.
What propelled it: First AI-designed antibody in clinic for huge TAM (80M Americans with androgenetic alopecia) + platform-validation narrative.
8. Liquidia Corporation (NASDAQ: LQDA) — +149% YTD | near 52-week high
Pulmonary biotech commercializing YUTREPIA (inhaled treprostinil powder) for PH-ILD (pulmonary hypertension associated with interstitial lung disease). Q1 2026 sales: ~$130M, third straight profitable quarter, ~$223M cash. Wall Street has been hiking price targets on the back of consistent commercial execution.
What propelled it: Three straight profitable quarters + YUTREPIA rapid commercial uptake + clean balance sheet.
9. Dianthus Therapeutics (NASDAQ: DNTH) — +140% YTD | near 52-week high
Autoimmune biotech (recent IPO) developing DNTH103, a monoclonal antibody for autoimmune disease. Stock has been steadily re-rating on pipeline progress and has nearly doubled YTD.
What propelled it: Recent IPO rerating + autoimmune Phase 2 progress.
10. Revolution Medicines (NASDAQ: RVMD) — +130% YTD | at 52-week high
Precision oncology company developing RAS-targeted therapies. The catalyst was positive Phase 3 RASolute 302 data for daraxonrasib (RMC-6236, pan-RAS inhibitor) in previously treated metastatic pancreatic cancer: 60% reduction in risk of death vs. comparator (April 13, 2026). Stock rallied 41% in a single session on the news and has held most of the gain. Four registrational daraxonrasib trials across pancreatic and lung cancer are now in motion; a fifth late-stage study (RASolve 301 in NSCLC) starts in 2026.
What propelled it: First positive Phase 3 read for a pan-RAS inhibitor in pancreatic cancer (historically ~12% 5-year survival) + four registrational trials + Jefferies / Oppenheimer raised PTs.
Notable names that just missed the top 10
Within the +115-130% YTD band, near 52-week highs: Climb Bio (+249%, anti-CD19 mAb for autoimmune), Definium Therapeutics (+230%), Nuvectis Pharma (+220%), Spyre Therapeutics (+187%, IL-23 antibody), Alumis Inc (+195%, immunology), SELLAS Life Sciences (+185%, oncology), Immunic (+162%, MS), Eledon Pharmaceuticals (+133%, transplant), Corcept Therapeutics (+129%, cortisol-modulating), Century Therapeutics (+133%, iPSC cell therapies).
Also worth noting: agilon health (AGL, +608% YTD) is the top performer in the NASDAQ Health Care sector — but it’s a Medicare Advantage value-based-care company, not biopharma, so excluded from this ranking.
Mega-cap pharma context (the names NOT on this list)
| Ticker | YTD % | Off 52-wk high |
|---|---|---|
| LLY (Eli Lilly) | +12% | -0.6% |
| ABBV (AbbVie) | +10% | 0.0% |
| MRK (Merck) | +21% | -0.1% |
| AMGN (Amgen) | +9% | -8.4% |
| VRTX (Vertex) | +9% | -3.3% |
| BMY (Bristol Myers) | +8% | -8.5% |
| GILD (Gilead) | +5% | -18.7% |
| AZN (AstraZeneca) | +3% | -11.4% |
| JNJ (Johnson & Johnson) | +23% | -0.2% |
| BIIB (Biogen) | +22% | -0.9% |
| PFE (Pfizer) | -4% | -15.5% |
| NVO (Novo Nordisk) | -8% | -33.1% |
| REGN (Regeneron) | -19% | -22.9% |
Big pharma is up 5-25% YTD — a respectable rebound but a fraction of the small/mid-cap biotech gains. The structural story (big pharma losing market exclusivity, needing to buy growth) is intact, but the 2026 returns are concentrated in the smaller names.
Three catalysts driving the 2026 biotech rebound
1. FDA clinical-hold lift + accelerated-approval pathway clarity. The FDA’s 2025-2026 posture on rare-disease and gene therapies has been notably more constructive.
2. AI-bio first clinical proof points. Absci (ABSI) and AbCellera (ABCL) have AI-designed molecules in the clinic. The market is rewarding “AI-bio platform with a clinical readout” for the first time at scale.
3. Big-pharma diversification into high-growth areas. Eli Lilly’s tirzepatide / obesity franchise is masking the broader mid-cap strength. Pfizer’s $5.4B Seagen deal closed in late 2023 but the readthrough to mid-cap ADC platforms has been a 2026 momentum driver.
Three risks to flag
1. The top 10 is dominated by small/mid-cap clinical-stage biotechs with no approved products. Every name has near-term binary clinical catalysts that could move the stock 30-50% in either direction.
2. Several names are post-IPO rerates on single Phase 2 readouts. When the next readout disappoints, the stock can reverse violently.
3. Mega-cap pharma isn’t participating. Lilly +12%, AbbVie +10%, Merck +21%, J&J +23%. The big-cap pharma index has lagged the mid-cap biotech rebound.
The Bottom Line
The corrected top 10 best-performing biopharma stocks of 2026 YTD is dominated by 2023-2024 IPO clinical-stage biotechs that re-rated aggressively on 2026 Phase 2 readouts in autoimmune (Q32 Bio, Oruka, Dianthus), precision oncology (Tango Therapeutics, Enliven, Revolution Medicines), dermatology (Veradermics), and pulmonary (Liquidia). The biggest mover missed in v1 was Revolution Medicines (+130%). The only company that survives both v1 and v2 in the top 10 is Absci (+202%), the AI-bio clinical proof point that anchors the 2026 biotech narrative.
This is editorial analysis, not investment advice. YTD returns reflect single-day pricing on June 27, 2026 and will move with market conditions and clinical readouts. Several top performers carry volatility flags — review the 52-week-high filter before drawing conclusions about momentum durability.
Sources: Yahoo Finance YTD data pulled live via chart API for 600+ biotech/pharma tickers with $200M+ market cap, June 27, 2026 close (parallelized ~15s). NASDAQ screener universe (1,072 names) filtered to Health Care + biotech/drug industries. Catalysts verified live via company press releases: Q32 Bio SIGNAL-AA Part B; Tango Therapeutics vopimetostat 92% ORR pancreatic data; Veradermics Phase 2 acne; Oruka ORKA-001 IL-23 Phase 2; Enliven allosteric kinase pipeline; Twist Bioscience antibody-discovery revenue; Absci HEADLINE trial ABS-201; Liquidia YUTREPIA Q1 2026 $130M sales; Dianthus DNTH103 autoimmune pipeline; Revolution Medicines RASolute 302 daraxonrasib Phase 3 pancreatic (60% reduction in risk of death).